We are developing the world's smallest single domain bispecific to enhance penetration of solid tumors and create a tighter immune synapse between tumor cells and effector cells...
Our Orthogonal Dual-Interacting Nanotherapeutic (ODIN) platform is designed to deliver disruptive, next generation single domain antibody-based technologies for the rapid development of highly potent immunotherapeutics.